US Stock MarketDetailed Quotes

ArriVent BioPharma (AVBP)

Watchlist
  • 25.460
  • -1.790-6.57%
Close Apr 10 16:00 ET
  • 25.460
  • 0.0000.00%
Post 20:01 ET
1.13BMarket Cap-5.89P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

ArriVent BioPharma (AVBP) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
88.25%177.53M
63.78%38.82M
58.12%38.32M
30.84%33.62M
222.98%66.77M
26.44%94.31M
2.54%23.71M
44.96%24.23M
13.78%25.7M
69.85%20.67M
Selling and administrative expenses
58.02%24.18M
87.69%6.65M
48.38%6.15M
50.63%5.9M
48.23%5.48M
57.68%15.3M
13.96%3.54M
70.11%4.14M
76.06%3.92M
91.06%3.7M
-General and administrative expense
58.02%24.18M
87.69%6.65M
48.38%6.15M
50.63%5.9M
48.23%5.48M
57.68%15.3M
13.96%3.54M
70.11%4.14M
76.06%3.92M
91.06%3.7M
Research and development costs
94.11%153.35M
59.57%32.18M
60.13%32.17M
27.28%27.72M
261.05%61.29M
21.76%79M
0.76%20.16M
40.67%20.09M
6.98%21.78M
65.84%16.98M
Operating profit
-88.25%-177.53M
-63.78%-38.82M
-58.12%-38.32M
-30.84%-33.62M
-222.98%-66.77M
-26.44%-94.31M
-2.54%-23.71M
-44.96%-24.23M
-13.78%-25.7M
-69.85%-20.67M
Net non-operating interest income expense
-18.77%11.23M
6.74%3.28M
-9.00%3.34M
-41.83%2.22M
-26.77%2.39M
162.89%13.82M
59.58%3.07M
58.44%3.67M
275.91%3.82M
3.26M
Non-operating interest income
-18.77%11.23M
6.74%3.28M
-9.00%3.34M
-41.83%2.22M
-26.77%2.39M
162.89%13.82M
59.58%3.07M
58.44%3.67M
275.91%3.82M
--3.26M
Other net income (expense)
Income before tax
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
Income tax
Net income
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
Net income continuous Operations
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
Minority interest income
Net income attributable to the parent company
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
Basic earnings per share
-68.75%-4.32
-27.87%-0.78
-36.07%-0.83
-38.46%-0.9
-171.43%-1.9
-17.99%-2.56
8.02%-0.61
-35.36%-0.61
3.69%-0.65
-83.78%-0.7
Diluted earnings per share
-68.75%-4.32
-27.87%-0.78
-36.07%-0.83
-38.46%-0.9
-171.43%-1.9
-17.99%-2.56
8.02%-0.61
-35.36%-0.61
3.69%-0.65
-83.78%-0.7
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 88.25%177.53M63.78%38.82M58.12%38.32M30.84%33.62M222.98%66.77M26.44%94.31M2.54%23.71M44.96%24.23M13.78%25.7M69.85%20.67M
Selling and administrative expenses 58.02%24.18M87.69%6.65M48.38%6.15M50.63%5.9M48.23%5.48M57.68%15.3M13.96%3.54M70.11%4.14M76.06%3.92M91.06%3.7M
-General and administrative expense 58.02%24.18M87.69%6.65M48.38%6.15M50.63%5.9M48.23%5.48M57.68%15.3M13.96%3.54M70.11%4.14M76.06%3.92M91.06%3.7M
Research and development costs 94.11%153.35M59.57%32.18M60.13%32.17M27.28%27.72M261.05%61.29M21.76%79M0.76%20.16M40.67%20.09M6.98%21.78M65.84%16.98M
Operating profit -88.25%-177.53M-63.78%-38.82M-58.12%-38.32M-30.84%-33.62M-222.98%-66.77M-26.44%-94.31M-2.54%-23.71M-44.96%-24.23M-13.78%-25.7M-69.85%-20.67M
Net non-operating interest income expense -18.77%11.23M6.74%3.28M-9.00%3.34M-41.83%2.22M-26.77%2.39M162.89%13.82M59.58%3.07M58.44%3.67M275.91%3.82M3.26M
Non-operating interest income -18.77%11.23M6.74%3.28M-9.00%3.34M-41.83%2.22M-26.77%2.39M162.89%13.82M59.58%3.07M58.44%3.67M275.91%3.82M--3.26M
Other net income (expense)
Income before tax -106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M-43.09%-17.42M
Income tax
Net income -106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M-43.09%-17.42M
Net income continuous Operations -106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M-43.09%-17.42M
Minority interest income
Net income attributable to the parent company -106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M-43.09%-17.42M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M-43.09%-17.42M
Basic earnings per share -68.75%-4.32-27.87%-0.78-36.07%-0.83-38.46%-0.9-171.43%-1.9-17.99%-2.568.02%-0.61-35.36%-0.613.69%-0.65-83.78%-0.7
Diluted earnings per share -68.75%-4.32-27.87%-0.78-36.07%-0.83-38.46%-0.9-171.43%-1.9-17.99%-2.568.02%-0.61-35.36%-0.613.69%-0.65-83.78%-0.7
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +10.02%
Sample Name
Sample Code
 +5.43%
Sample Name
Sample Code
 +2.46%
4
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
+1.46%
5
United Sts 12 Month Oil Fd Lp Unit Ben Int
USL
+0.70%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +12.34%
Sample Name
Sample Code
 +11.49%
Sample Name
Sample Code
 +10.29%
4
Futu Holdings Ltd
FUTU
+10.23%
5
Hesai
HSAI
+9.84%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 12 local time, U.S. Vice President Vance stated that negotiations between the United States and Iran failed to reach an agreement, Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -